Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Gyre Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 48 | 44 | −4 |
| Shares | 3.10M | 3.34M | +249.0K (+8.0%) |
| Value | $23.1M | $23.6M | +$522.1K (+2.3%) |
New holders (2)
Institutions that held Gyre Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Dimensional Fund Advisors LP | 10,903 | $77.0K | 0.00% |
| Smartleaf Asset Management LLC | 6 | $42 | 0.00% |
Sold out (6)
Institutions that held Gyre Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Millennium Management LLC | 35,751 | $266.7K |
| Lazard Asset Management LLC | 14,932 | $111.4K |
| Jane Street Group, LLC | 12,958 | $96.7K |
| Principal Securities, Inc. | 85 | $634 |
| Advisory Services Network, LLC | 66 | $492 |
| SRS Capital Advisors, Inc. | 57 | $426 |